Leading Cancer Center in Japan Selects Hyperion Imaging System to Expand Immuno-Oncology Research Studies in Colorectal Cancer

Fluidigm Corporation (NASDAQ:FLDM) declared today that the Group for Innovative Cancer Treatment Division of the National Cancer Center in Japan has extended its clinical research in colorectal malignancy utilizing the Hyperion™ Imaging System to contemplate administrative T (Treg) cell multiplication in tumor tissue with the objective of finding a novel focus for immunotherapy. Globally, colorectal cancer is the third-most commonly occurring cancer in men and the second-most common in women. There were more than 1.8 million new cases worldwide in 2018.

Treg cells, a specialized subpopulation of T cells, are actively engaged in the maintenance of immunological self-tolerance and homeostasis. They are more frequently observed in tumor than in non-tumor tissue and are known to inhibit the development of effective anti-tumor immune responses.

“The Hyperion Imaging System provides a wealth of information from each tumor tissue sample by simultaneous analysis of up to 37 protein markers, providing a critical capability in our research into a potential therapy for colorectal cancer,” said Nishikawa. “This technology is an extremely valuable tool in our translational research and drug discovery efforts.”

Mass cytometry deeply profiles immune cell phenotypes and function and is the basis of hundreds of peer-reviewed publications documenting research on the frontiers of immunology, immuno-oncology and other realms of health and disease. The Hyperion Imaging System extends the use of mass cytometry technology and is revolutionizing high-multiplex tissue analysis by deeply characterizing the tumor microenvironment with an efficient one-scan workflow.

“The National Cancer Center has picked the Hyperion Imaging System to profoundly examine tissue tests for basic immuno-oncology work, and we are genuinely energized that our innovation is supporting examination toward a potential future treatment for a malady as universally common as colorectal malignancy,” said Chris Linthwaite, Fluidigm President and CEO.

“This is one more case of multisystem arrangement in chief research focuses that use our spearheading mass cytometry and Imaging Mass Cytometry™ frameworks to distinguish important biomarkers and quicken advancement of progressively effective treatments,” Linthwaite said.